2-(pentyloxy)benzoic acid | 2200-82-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(pentyloxy)benzoic acid
• 英文别名: 2-pentoxybenzoic acid
• CAS: 2200-82-0
• 化学式: C₁₂H₁₆O₃
• mdl: MFCD06447131
• 分子量: 208.257
• InChiKey: CNCMJNMYQXOHNN-UHFFFAOYSA-N

物化性质

• 熔点：
  30-32 °C
• 沸点：
  182-185 °C(Press: 1 Torr)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(pentyloxy)benzoic acid 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 苯 为溶剂， 反应 5.0h， 生成 2-n-Pentyloxyphenylisocyanat
  参考文献：
  名称：

  Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement

  摘要：

  A series of 1-phenyl-3-(1-phenylethyl)urea derivatives were identified as novel and potent complement inhibitors through structural modification of the original compound from high-throughput screening. Various analogues (7 and 13-15) were synthesized and identified as complement inhibitors, with the introduction of a five- or six-carbon chain (7c, 7d, 7k, 7I, and 7o) greatly improving their activity. Optimized compound 7I has an excellent inhibition activity with IC50 values as low as 13 nM. We demonstrated that the compound 7I inhibited C9 deposition through the classical, the lectin, and the alternative pathways but had no influence on C3 and C4 depositions.

  DOI：

  10.1021/ml300005w
• 作为产物：
  描述：

  甲基2-(戊氧基)苯甲酸酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2-(pentyloxy)benzoic acid
  参考文献：
  名称：

  咪唑并吡啶抑制环核苷酸磷酸二酯酶：舒马唑和异唑的类似物作为cGMP特异性磷酸二酯酶的抑制剂。

  摘要：

  描述了一系列咪唑并吡啶（包括舒马唑和异唑）对分离的PDE同工酶的合成和磷酸二酯酶（PDE）抑制谱。结果表明，舒马唑和异咪唑都是PDE III的弱抑制剂，它们的正性活性不太可能仅由于PDE III的抑制而引起。出乎意料的是，发现这两种化合物都是cGMP特异性同工酶PDE V的重要抑制剂，并且已经制备了一系列简单的2-取代的苯基咪唑并[4,5-b]吡啶用于研究PDE活性的SAR。已显示这对链长，极性和杂原子连接基团的性质敏感。已经确定了有效的PDE V抑制剂，其中许多也是PDE IV的重要抑制剂。

  DOI：

  10.1021/jm00062a011

文献信息

• New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships
  作者：Hisao Nakai、Mitoshi Konno、Shunji Kosuge、Shigeru Sakuyama、Masaaki Toda、Yoshinobu Arai、Takaaki Obata、Nobuo Katsube、Tsumoru Miyamoto

  DOI：10.1021/jm00396a013

  日期：1988.1

  (p-Amylcinnamoyl)anthranilic acid (3a) had moderate antagonist activities against LTD4-induced smooth muscle contraction on guinea pig ileum and LTC4-induced bronchoconstriction in anesthetized guinea pigs. Modifications were made in the hydrophobic part (cinnamoyl moiety) and the hydrophilic part (anthranilate moiety) of 3a. A series of 8-(benzoylamino)-2-tetrazol-5-yl-1,4-benzodioxans and 8-(ben

  （p-戊基肉桂酰基）邻氨基苯甲酸（3a）对LTD4-诱导的豚鼠回肠平滑肌收缩和LTC4诱导的豚鼠支气管收缩具有中等程度的拮抗活性。对3a的疏水部分（肉桂酰基部分）和亲水部分（邻氨基苯甲酸酯部分）进行了修饰。揭示了一系列的8-（苯甲酰基氨基）-2-四唑-5-基-1，4-苯并二恶烷和8-（苯甲酰基氨基）-2-四唑-5-基-4-氧代-4H-1-苯并吡喃。白三烯C4和D4的有效拮抗剂。在这两个系列中，ONO-RS-347（18k）和ONO-RS-411（19h）分别是最有效和口服活性的拮抗剂。讨论了构效关系。
• Oral care compositions with color changing indicator
  申请人：Sabnis W. Ram

  公开号：US20060222601A1

  公开（公告）日：2006-10-05

  The invention describes color changing toothpastes and mouthwashes which contains acid-base indicator(s) for interaction with the oral cavity to provide a color change indicative of treatment time.

  这项发明描述了含有酸碱指示剂的变色牙膏和漱口水，用于与口腔相互作用，以提供治疗时间的颜色变化指示。
• Phenylalanine derivative and proteinase inhibitor
  申请人：Okamoto, Shosuke

  公开号：EP0284632A1

  公开（公告）日：1988-10-05

  A phenylalanine derivative having the formula (I): wherein A represents (a) H2N-, (b) or B represents (a) (b) or wherein m is 0, 1, or 2 and n is 3, 4, or 5; X represents (a) hydroxy, (b) nitro, (c) amino, (d) phenoxy which may be substituted with (i) halogen or (ii) nitro, (e) C1-C4 alkyloxy which may be substituted with (i) phenyl or (ii) benzoyl, (f) benzoyl, (g) pyridyloxy which may be substituted with (i) halogen or (ii) nitro, or (h) C1-C4 alkyl which may be substituted with halogen; Y represents or -OR3 wherein R1 and R2 are independently (a) hydrogen, (b) phenyl which may be substituted with (i) benzoyl, (ii) C1-C4 alkylcarbonyl, (iii) C1-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl or hydroxycarbonyl, (iv) C2-Cs alkenyl which may be further substituted with hydroxycarbonyl or C1-C4 alkoxycarbonyl, (v) C1-C4 alkoxycarbonyl, or (vi) amidino, (c) pyridyl which may be substituted with halogen or carboxyl (d) imidazolyl, (e) pyrimidyl, (f) tetrazolyl, (g) thiazolyl which may be substituted with C,-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl, (h) C1-C6 alkyl which may be substituted with C1-C4 alkoxy, C1-C4 alkoxycarbonyl, phenyl, or benzoyl, (i) CS-C7 cycloalkyl which may be substituted with C1-C4 alkoxycarbonyl or (j) R' and R2 may form, with the nitrogen atom attached thereto, (i) pyperazyl which may be substituted on the nitrogen atom with C1-C4 alkyl which may be further substituted with phenyl, (ii) piperidino which may be substituted with carboxyl or C1-C4 alkoxycarbonyl, (iii) pyrrolidyl which may be substituted with C1-C4 alkoxycarbonyl, or (iv) morpholyl; and R3 represents (a) hydrogen, (b) C1-C6 alkyl which may be substituted with (i) C1-C4 alkoxy, (ii) phenyl, or (iii) pyridyl, or (c) pyridyl; or a pharmaceutically acceptable acid salt thereof. This phenylalanine derivative is effective as a proteinase.

  具有以下式（I）的苯丙氨酸衍生物：其中A代表（a）H2N-，（b）或B代表（a）（b）或其中m为0、1或2，n为3、4或5；X代表（a）羟基，（b）硝基，（c）氨基，（d）苯氧基，其可以被（i）卤素或（ii）硝基取代，（e）C1-C4烷氧基，其可以被（i）苯基或（ii）苯甲酰基取代，（f）苯甲酰基，（g）吡啶氧基，其可以被（i）卤素或（ii）硝基取代，或（h）C1-C4烷基，其可以被卤素取代；Y代表或-OR3，其中R1和R2独立地为（a）氢，（b）苯基，其可以被（i）苯甲酰基，（ii）C1-C4烷基羰基，（iii）C1-C4烷基，其可以进一步被C1-C4烷氧羰基或羟基羰基取代，（iv）C2-Cs烯烃基，其可以进一步被羟基羰基或C1-C4烷氧羰基取代，（v）C1-C4烷氧羰基，或（vi）酰胺基，（c）吡啶基，其可以被卤素或羧基取代（d）咪唑基，（e）嘧啶基，（f）四唑基，（g）噻唑基，其可以被C1-C4烷基取代，其可以进一步被C1-C4烷氧羰基取代，（h）C1-C6烷基，其可以被C1-C4烷氧基，C1-C4烷氧羰基，苯基或苯甲酰基取代，（i）C5-C7环烷基，其可以被C1-C4烷氧羰基取代或（j）R'和R2可以与其连接的氮原子形成（i）哌嗪基，其可以在氮原子上被C1-C4烷基取代，其可以进一步被苯基取代，（ii）哌啶基，其可以被羧基或C1-C4烷氧羰基取代，（iii）吡咯基，其可以被C1-C4烷氧羰基取代，或（iv）吗啉基；R3代表（a）氢，（b）C1-C6烷基，其可以被（i）C1-C4烷氧基，（ii）苯基或（iii）吡啶基取代，或（c）吡啶；或其药学上可接受的酸盐。该苯丙氨酸衍生物作为蛋白酶具有有效性。
• Structure–Activity Relationship Study of <i>N</i><sup>6</sup>-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production
  作者：Seika Amemiya、Takao Yamaguchi、Taki Sakai、Yuichi Hashimoto、Tomomi Noguchi-Yachide

  DOI：10.1248/cpb.c16-00410

  日期：——

  Bromodomains are epigenetic ‘readers’ of histone acetylation. The first potent bromodomain and extra-terminal domain (BET) inhibitors, (+)-JQ1 and I-BET762 (also known as GSK525762), were reported in 2010. Some BET inhibitors are already under clinical trial for the treatment of cancers, but so far, only a few chemical scaffolds are available. We have reported potent N6-benzoyladenine-based inhibitors of BRD4, a BET family member that serves as a key mediator of transcriptional elongation. Here we present an analysis of the structure–activity relationships of these inhibitors. Among the compounds examined, 20, 28 and 29 enhanced all-trans retinoic acid (ATRA)-induced HL-60 cell differentiation and inhibited tumor necrosis factor (TNF)-α production by THP-1 cells.

  溴结构域是组蛋白乙酰化的表观遗传 "阅读器"。2010 年报道了第一种强效溴化多域和末端外域（BET）抑制剂--(+)-JQ1 和 I-BET762（又称 GSK525762）。一些 BET 抑制剂已用于治疗癌症的临床试验，但迄今为止，只有少数化学支架可用。我们已经报道了基于 N6-苯甲酰基腺嘌呤的 BRD4 强效抑制剂，BRD4 是一种 BET 家族成员，是转录伸长的关键介质。在此，我们对这些抑制剂的结构-活性关系进行了分析。在所研究的化合物中，20、28 和 29 增强了全反式维甲酸（ATRA）诱导的 HL-60 细胞分化，并抑制了 THP-1 细胞产生肿瘤坏死因子（TNF）-α。
• The chemotherapy of schistosomiasis. Part VIII. 2-Carboxy- and 2-carbamoyl-4-aminophenyl ethers
  作者：R. F. Collins、M. Davis

  DOI：10.1039/j39660002196

  日期：——

  Synthetic work in the series of schistosomicidal p-aminophenyl ethers has been continued with the introduction of carboxy-, carbamoyl-, alkylsulphonyl-, and some miscellaneous nuclear substituents for structure–activity studies.

  通过引入羧基-，氨基甲酰基-，烷基磺酰基-和一些其他核取代基进行结构活性研究，继续进行了一系列血吸虫的对氨基苯醚的合成工作。